Howell, S J, Casbard, A, Carucci, M, Ingarfield, K, Butler, R, Morgan, S, Meissner, M, Bale, C, Bezecny, P, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, de Bruin, E C, Schiavon, G, Foxley, A & Jones, R H 2022, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION) : overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial ', The Lancet. Oncology, vol. 23, no. 7, pp. 851-864 . https://doi.org/10.1016/S1470-2045(22)00284-4
International Journal of Radiation Oncology, Biology, Physics Huddart, R, Hafeez, S, Lewis, R, McNair, H, Syndikus, I, Henry, A, Staffurth, J, Dewan, M, Vassallo-Bonner, C, Moinuddin, S A, Birtle, A, Horan, G, Rimmer, Y, Venkitaraman, R, Khoo, V, Mitra, A, Hughes, S, Gibbs, S, Kapur, G, Baker, A, Hansen, V N, Patel, E, Hall, E & HYBRID Investigators 2021, ' Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer ', International Journal of Radiation Oncology, Biology, Physics, vol. 110, no. 2, pp. 412-424 . https://doi.org/10.1016/j.ijrobp.2020.11.068
Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 345-357 . https://doi.org/10.1016/S1470-2045(19)30817-4